Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

NCT03371979 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: Pegzilarginase
DRUG: Pembrolizumab

Sponsor

Aeglea Biotherapeutics

Collaborators

[object Object]